Pharma's Almanac TV
PA TV
Dashboard
Your Name
Your Email
Manage Account
Sign Out
Sign In
Register
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Research
CDMO
CRO
Excipients
Pharmaceutical Equipment
Pharmaceutical Intermediates
Supply Chain Logistics
Magazine
Current Issue
Archive
Community
Company A to Z
Content Filter
More+
Staffing
Media Kit
By The Numbers
Clinical Data
75 Articles Available
1
4
Can't find what you're looking for? Try our
advanced search
.
Gene Editing
Vertex Announces New Clinical Data for Investigational Gene-Editing Therapy CTX001™ in Severe Hemoglobinopathies
PR-M06-20-NI-017
PR-M03-20-NI-036
Vaccitech and Oxford University Announce Promising Phase 2a Data on Prostate Cancer Immunotherapy
PR-M03-20-NI-036
Cell and Gene Therapy
CRISPR Therapeutics and Vertex Announce Positive Safety and Efficacy Data From First Two Patients Treated With Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001® for Severe Hemoglobinopathies
PR-M11-19-NI-023
Endpoints
Sanifit Announces the Phase 2b CaLIPSO Trial of SNF472 Met Endpoint in Slowing the Cardiovascular Calcification in Patients on Hemodialysis
PR-M10-19-NI-051
Clinical Data
Mirati Therapeutics Presents First Clinical Data of Phase 1/2 Trial of MRTX849
PR-M10-19-NI-043
Clinical Results
TG Therapeutics Announces Positive Results from the UNITY-NHL Phase 2b Pivotal Trial Evaluating Umbralisib Monotherapy in Patients with Relapsed/Refractory Follicular Lymphoma
PR-M10-19-NI-042
Clinical Study
Biogen Plans Regulatory Filing for Aducanumab in Alzheimer’s Disease Based on New Analysis of Larger Dataset from Phase 3 Studies
PR-M10-19-NI-031
Clinical Data
New Data Reinforces Benefits of Spiolto® Respimat® in Improving Patient Outcomes
PR-M10-19-NI-001
Clinical Data
Concert Pharmaceuticals Reports Positive CTP-543 Results from Phase 2 Alopecia Areata Trial
PR-M09-19-NI-010
Clinical Data
Transgene Provides Update on PHOCUS Study of Pexa-Vec in Liver Cancer Following Planned Interim Futility Analysis
PR-M08-19-NI-015
Gene Therapy
Amicus Announces Positive Interim Clinical Data for AAV Gene Therapy in Children with CLN6 Batten Disease
PR-M08-19-NI-011
Clinical Progress
Sage Therapeutics Announces Clinical Updates and Progress Across Neuroscience Pipeline During “Sage FutureCast”
PR-M07-19-NI-067
Clinical Data
Pfizer Presents Initial Clinical Data on Phase 1b Gene Therapy Study for Duchenne Muscular Dystrophy (DMD)
PR-M07-19-NI-017
Clinical Trials
Krystal Biotech Announces Positive Results from Phase 2 Clinical Trial and Receives Regenerative Medicine Advanced Therapy Designation
PR-M06-19-NI-047
Diabetes
Common Glycemic Control Drug Could Have Other Significant Positive Effects for Type 2 Diabetes Patients
PAO-M06-19-NI-012
Clinical Data
Enanta Pharmaceuticals Announces Positive Topline Results in Healthy Adults Infected with Respiratory Syncytial Virus (RSV)
PR-M06-19-NI-028
Clinical Trials
GBT Announces Efficacy Data from All Patients Enrolled in Phase 3 Study Sustained Improvements in Hemoglobin with Voxelotor
PR-M06-19-NI-025
Clinical Data
New Long-Term Data Show that Twice-a-Year Dosing with Inclisiran Results in Persistent Lowering of LDL Cholesterol
PR-M05-19-NI-064
Endpoints
MorphoSys AG: Primary Endpoint of L-MIND, a Combination Study of Tafasitamab (MOR208) and Lenalidomide, Has Been Met, Confirming Previously Published Activity
PR-M05-19-NI-065
Biosimilar
Successful Results Reported for Another Rituximab Biosimilar
PAO-M05-19-NI-020
Clinical Trial Data
Achillion Reports Positive Interim Data for ACH-4471 Phase 2 Combination Trial with Eculizumab at The New Era of Aplastic Anemia and PNH Meeting
PR-M05-19-NI-060
Vaccines
Moderna Announces Publication of Phase 1 Data for mRNA Vaccines Against Two Potential Pandemic Influenza Strains
PR-M05-19-NI-041
Trial Update
Merck Provides Update on Phase 3 KEYNOTE-062 Trial
PR-M04-19-NI-085
Clinical Data
United BioPharma Announces Publication of Breakthrough HIV Clinical Trial Data in the New England Journal of Medicine
PR-M04-19-NI-066
1
4
»
